The customer reported an adverse reaction to the product swab with the binaxnow covid-19 antigen self test.Per the customer, the customer was experiencing multiple symptoms over a time period.Additionally, the customer stated this from repeat exposure to the binaxnow covid-19 ag card.The first two weeks were okay.Starting on the third week, immediately after testing, there was a burning sensation followed by numbness where the swab contacted the nose.The numbness faded within a few hours.The customer also stated that the problems are getting more pronounced with each exposure.This was reported to fda in medwatch report mw5104435.Although requested, additional information, including patient treatment and outcome was not provided.
|
Investigation report: the manufacturing records and quality control release testing was reviewed for kit part number 195-000/ lot 154369 and device part number 195-430h/ lot 146669a.Quality control release testing met specifications.The manufacturing batch records were also reviewed for swab component part number pk002720/ lot 2021020071 and lot 2021020033 and were found to meet release specifications.The information to enable further investigation was not provided and an investigation was not able to be performed.Notwithstanding, complaints against these trend codes are monitored to identify and track any out-of-trend/unexpected performance at the lot and product family level.Based on the above summary, the investigation is deemed complete.The product will continue to be monitored and tracked.
|